Aytu BioPharma to Present at Upcoming September 2025 Conferences
Rhea-AI Summary
Aytu BioPharma (Nasdaq:AYTU), a pharmaceutical company specializing in innovative medicines for complex central nervous system diseases, has announced its participation in two upcoming investor conferences in September 2025.
Management will present at the MicroCap Rodeo Fall Conference in New York City on September 25, 2025, at 2:00 PM ET, and at the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025, at 2:45 PM ET. Both presentations will be available via webcast, and management will conduct one-on-one meetings during both events.
Positive
- None.
Negative
- None.
News Market Reaction – AYTU
In the Sep 25 session, AYTU declined 9.71%, reflecting a notable negative market reaction. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 5.4x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENVER, CO / ACCESS Newswire / September 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced management will participate at the following investor conferences:
MicroCap Rodeo Fall Conference
Date: Thursday, September 25, 2025
Location: New York City
Presentation Time: 2:00 p.m. Eastern time
Webcast: https://www.webcaster5.com/Webcast/Page/3142/53024
Lytham Partners Fall 2025 Investor Conference
Date: Tuesday, September 30, 2025
Location: Virtual
Presentation Time: 2:45 p.m. Eastern time
Webcast: https://app.webinar.net/K8vDlaelmAd
Management will be participating in one-on-one meetings throughout both events. To arrange a meeting with management, please contact Robert Blum of Lytham Partners at aytu@lythampartners.com.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD), Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotempla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), and a line of legacy products, including Karbinal® ER (carbinoxamine maleate), Poly-Vi-Flor® and Tri-Vi-Flor®. To learn more, please visit aytubio.com.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
rselhorn@aytubio.com
Robert Blum
Lytham Partners
aytu@lythampartners.com
SOURCE: Aytu BioPharma, Inc.
View the original press release on ACCESS Newswire